Gastroenterology
Antonio Gasbarrini, director of CEMAD at the Gemelli Hospital in Rome, explains how the microbiome clinics will help us against a variety of diseases.
A gut dysbiosis leads to an increase in proline, which gives C. difficile a competitive advantage and favors the development of the infection.
Scott Snapper, professor at Harvard Medical School, talks about IBD and therapeutic possibilities based on the manipulation of the intestinal microbiota.
Exosome-like nanoparticles derived from plants contain RNAs that regulate gut microbiota composition and impact on the gut barrier function.
In the pathogenesis of IBDs, the gut microbiota plays a key role. Treating gut dysbiosis may be a solutions, so companies are exploring this possibility.
Migrating to a western country alters the intestinal microbiome and provides a key to understanding metabolic diseases such as obesity.
